Paracetamol is one of the most boring molecules in pharmaceutical chemistry. It is off-patent, manufactured by hundreds of factories, and available in dozens of formulations across every price point. There is nothing proprietary about it. Nothing defensible. Nothing that should, by any commercial logic, allow one brand to dominate it for five decades.
And yet, if someone in an Indian household feels a fever coming on, they rarely say "get me paracetamol." They say "get me a Crocin."
That is not an accident. It is the result of one of the most carefully executed brand-building playbooks in Indian pharma history — and understanding how it happened teaches you more about pharma marketing strategy than most textbooks ever will.
The problem with selling a commodity
Before getting into Crocin specifically, it helps to understand why branding a generic molecule is so difficult in the first place.
When a molecule is off-patent, any manufacturer can make it. That means the product itself offers no differentiation — the paracetamol in a Crocin strip and the paracetamol in a ₹5 generic are chemically identical. In that situation, the only things a company can compete on are price, distribution, and brand perception.
Competing on price is a race to the bottom. Competing on distribution is slow and expensive. Competing on brand perception — making consumers feel that your version of the molecule is somehow safer, more reliable, or more effective — is the only sustainable path. But it requires the consumer to trust you. And in healthcare, trust is not bought with a catchy jingle. It has to be earned over time, through consistent presence, clear messaging, and association with the moments that matter.
Crocin understood this early. Most of its competitors did not.
Breaking the push model
The standard pharma marketing model in India — for most of its history — has been what the industry calls a push strategy. You deploy a sales force of medical representatives who visit doctors, present clinical data, leave branded samples, and hope the doctor writes your brand name on the next relevant prescription. The patient never chooses. The doctor chooses for them.
This model works well for prescription drugs. For a molecule like paracetamol — available over the counter, used for everyday ailments, and bought without a prescription by millions of Indians every month — it leaves enormous consumer value on the table.
Crocin's early move was to go directly to the consumer. Mass media advertising, simple and memorable messaging focused on fast relief from fever, headache, and body pain, and aggressive visibility at retail pharmacies. The goal was not to get into the doctor's prescription pad. The goal was to get into the family medicine cabinet — and stay there.
This was a first-mover advantage that proved almost impossible to dislodge. Once a brand becomes the household default for a common ailment, switching costs are not rational — they are emotional. You do not switch from Crocin because you calculated that a generic is better value. You switch only if something shakes your trust. And Crocin gave consumers very little reason to lose trust.
The pincer that nobody talks about
Here is the part of the Crocin story that most people — including most pharma students — have never heard explained clearly.
When GlaxoSmithKline Consumer Healthcare controlled both Crocin and Calpol in the Indian market, they were running two separate brands built on the exact same molecule. From the outside, this looks redundant. Why maintain two paracetamol brands? Why not consolidate?
The answer is that Calpol and Crocin were never competing with each other. They were each capturing a completely different purchasing moment.
Calpol — the prescription trust brand
Calpol was a professional push brand. It was marketed almost entirely to doctors — specifically paediatricians — through medical representatives and clinical detailing. Parents did not choose Calpol. Doctors prescribed it, and parents accepted it without question because a doctor had recommended it. In healthcare, a doctor's recommendation functions as institutional trust. You do not second-guess it.
Crocin — the consumer pull brand
Crocin was a consumer pull brand. It owned the retail shelf, the self-medication moment, and the top-of-mind recall that makes a consumer reach for a specific product without thinking. When a working adult woke up with a headache and walked to the nearest pharmacy without a prescription, they asked for Crocin.
Together, the two brands covered both moments of purchase: the prescription pad and the pharmacy shelf. A competitor entering the paracetamol market would have to displace both simultaneously to make meaningful inroads. That is an extraordinarily expensive problem to solve.
This is what a dual-brand pincer strategy looks like in practice. It is not about having two brands for its own sake. It is about leaving no purchasing moment undefended.
The pricing regulation that changed everything
To understand the Dolo 650 disruption, you first have to understand what DPCO does to a branded generic market.
The Drug Price Control Order puts price ceilings on essential medicines listed under the National List of Essential Medicines. Paracetamol 500mg has been on that list for years. That means every brand — Crocin, Calpol, and hundreds of competitors — is selling at a ceiling price set by the government. There is no room to charge a premium on the standard formulation. If you want to understand how DPCO price ceilings are calculated, the drug pricing article covers this in detail.
Now here is the strategic gap that Dolo identified: the 650mg formulation of paracetamol was, at the time Dolo entered aggressively, not on the NLEM price control list. A 650mg tablet is not a standard formulation. It is a slightly higher dose — technically a different product. And because it sat outside the price ceiling, a manufacturer could set their own MRP, offer much higher trade margins to pharmacists, and build a much larger promotional budget for the sales force pushing it to doctors.
The strength-variation loophole — making a slightly different dose to step outside DPCO price controls — is the same principle described in the drug pricing article. Dolo applied it to the most competitive molecule in the Indian OTC market. That is what made it so effective.
How Dolo built a clinical narrative instead
Dolo's strategy was specifically clinical. Rather than going head-to-head with Crocin on consumer advertising — which would have been expensive and slow — they built a medical narrative around the 650mg dose.
The specific indication they focused on was Fever of Unknown Origin: prolonged, unexplained fevers where a doctor needs something between a standard OTC dose and a prescription-grade antipyretic. The 650mg dose positioned itself as the clinically appropriate middle ground — and it was detailed aggressively to physicians.
Doctors began prescribing it. Prescriptions circulated. Pharmacists stocked it because the margins were better. And then the pandemic arrived.
What COVID-19 did to the paracetamol market
The pandemic changed the competitive dynamics of this market in a way that Crocin's consumer pull strategy was structurally unprepared for.
When COVID-19 hit, fever became a medical emergency, not a minor inconvenience. Consumer behaviour shifted almost overnight from self-medication and retail familiarity to professional medical authority. People were not reaching for the brand in their medicine cabinet. They were calling doctors, following prescriptions on WhatsApp, and buying whatever their doctor had recommended.
Dolo 650 was already deeply embedded in the prescription market. The pandemic amplified that position dramatically. Doctors who had been prescribing it for FUO protocols had it top of mind. It circulated rapidly through digital prescription sharing. Supply chains held. And because it had become the go-to prescribed paracetamol during the crisis, it built exactly the kind of institutional trust with both doctors and patients that Crocin had built with consumers over decades — just faster, and in a completely different channel.
The story is not that Crocin collapsed — it did not. The story is that Dolo proved that Crocin's consumer pull moat, however strong, was not the only way to build a dominant paracetamol brand.
How Crocin is responding
Crocin's response to the 650mg challenge has been brand architecture — introducing premium variants that sit outside the standard price ceiling and justify higher pricing through product differentiation.
Crocin Advance is positioned around faster absorption. The brand claims a significantly quicker disintegration than a standard tablet using a technology called Optizorb. Whether the clinical difference is meaningful to most patients is debatable. What it does commercially is allow the brand to price above the DPCO ceiling for standard 500mg and position itself as an upgrade, not a commodity.
Crocin Pain Relief — which combines paracetamol with caffeine — and Crocin Cold and Flu are examples of the same logic applied to occasion-specific marketing. Caffeine as a pain potentiator is a legitimate pharmacological combination. It is also a way to create a distinct product that a competitor cannot directly copy at the same price point.
The broader strategic direction is to move Crocin away from being a single-formulation commodity brand toward a portfolio of targeted symptom solutions — each serving a specific consumer occasion, each sitting at a price point that is insulated from generic competition. Whether this fully recovers the ground lost to Dolo in the prescription segment remains an open question.
What this playbook teaches you
The Crocin story is not really about paracetamol. It is about the strategic choices a brand makes when it cannot compete on the molecule itself.
Consumer pull versus professional push is not a binary choice — the most sophisticated brands find ways to own both. The dual-brand pincer was not an accident. It was a deliberate decision to leave no purchasing moment undefended.
Pricing regulation does not just constrain brands — it creates gaps that challengers exploit. Dolo did not beat Crocin on advertising spend or brand heritage. It found a regulatory arbitrage, built a clinical narrative around it, and executed in exactly the channel Crocin had under-invested in.
And brand architecture — extending a core brand into variants with distinct positioning — is how a branded generic stays ahead of commoditisation. Not by making the molecule better, but by making the brand mean something specific to a specific consumer in a specific moment.
This is what brand strategy actually looks like in pharma. Not logos and taglines. Positioning under constraint.
If this was useful, the next article worth reading is on how drug pricing in India actually works — which explains the DPCO mechanics and pricing loopholes that sit behind the Dolo disruption described here.